09:55 AM EDT, 06/03/2025 (MT Newswires) -- Enveric Biosciences ( ENVB ) said Tuesday it has been granted a new US patent covering a structurally diverse class of novel molecules with potential therapeutic use in treating sleep and central nervous system disorders.

The patent expands the company's intellectual property portfolio and supports its drug discovery platform focused on CNS conditions, Enveric said.

The newly patented compounds include potential MT1-selective agonists for next-generation sleep therapeutics and others that target additional CNS-relevant receptors, supporting broader psychiatric applications and building on the clinically validated melatonin signaling pathway, the biotechnology company said.

Shares of Enveric Biosciences ( ENVB ) were up 1.6% in recent early trading.

Price: 1.25, Change: +0.02, Percent Change: +1.63